Document is current
Any future updates will be listed below
-
Authors
DeGolier, Kole R. https://orcid.org/0000-0002-4144-7277
Danis, Etienne
D’Antonio, Marc
Cimons, Jennifer https://orcid.org/0000-0002-8111-8697
Yarnell, Michael https://orcid.org/0000-0002-4557-7255
Kedl, Ross M. https://orcid.org/0000-0002-9065-7895
Kohler, M. Eric https://orcid.org/0000-0002-1181-0418
Scott-Browne, James P. https://orcid.org/0000-0002-0546-7799
Fry, Terry J. https://orcid.org/0000-0001-8044-5226
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-19-1-0196)
Foundation for the National Institutes of Health (P30CA046934)
- License Information
-
More Information
Article History
Received: 5 December 2023
Accepted: 11 November 2024
First Online: 2 January 2025
Competing interests
: The University of Colorado Anschutz Medical Campus has filed a patent application, PCT/US2024/054159, regarding compositions and methods of enhancing immune cell therapies by RUNX2 modulation, with K.R.D., J.P.S.-B. and T.J.F. listed as inventors. The other authors have no competing interests.
